Cover Image
市場調查報告書

白細胞介素 (IL15):開發中產品分析

Interleukin 15 (IL15) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365734
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
白細胞介素 (IL15):開發中產品分析 Interleukin 15 (IL15) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 44 Pages
簡介

本報告提供以白細胞介素 (IL15)為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

白細胞介素 (IL15) 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Calypso Biotech SA
  • Digna Biotech, S.L.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0125TDB

Summary

Global Markets Direct's, 'Interleukin 15 (IL15) - Pipeline Review, H1 2016', provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 15 (IL15), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 15 (IL15) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 15 (IL15)
  • The report reviews Interleukin 15 (IL15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 15 (IL15) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 15 (IL15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 15 (IL15) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 15 (IL15)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 15 (IL15) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interleukin 15 (IL15) Overview
  • Therapeutics Development
    • Interleukin 15 (IL15) - Products under Development by Stage of Development
    • Interleukin 15 (IL15) - Products under Development by Therapy Area
    • Interleukin 15 (IL15) - Products under Development by Indication
  • Interleukin 15 (IL15) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Interleukin 15 (IL15) - Products under Development by Companies
  • Interleukin 15 (IL15) - Products under Development by Universities/Institutes
  • Interleukin 15 (IL15) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interleukin 15 (IL15) - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Calypso Biotech SA
    • Digna Biotech, S.L.
  • Interleukin 15 (IL15) - Drug Profiles
    • AM-0015 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-714 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNZ-1321 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNZ-1322 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CALY-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DB-039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit IL-2 and IL-15 for Oncology, Central Nervous System and Gastrointestinal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Activate IL-15 for Prostate Cancer and Metastatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interleukin 15 (IL15) - Dormant Projects
  • Interleukin 15 (IL15) - Discontinued Products
  • Interleukin 15 (IL15) - Featured News & Press Releases
    • May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease
    • Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II
    • Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting
    • Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Celiac Disease Symposium
    • Jun 18, 2015: Admune Announces the First-in-Human Study of Heterodimeric IL-15 with Broad Applications for Cancer Immunotherapy
    • Dec 15, 2006: Genmab Announces AMG 714 Development Update
    • Mar 23, 2004: Amgen Announces Positive Humax-IL15 Interim Phase II Data
    • Jan 23, 2003: Genmab A/S Announces FDA Approval To Initiate Phase II Clinical Study Using HuMax-IL15
    • Sep 04, 2002: Genmab Announces Positive Results From Phase I/II Clinical Trial Of HuMax-IL15 For The Treatment Of Rheumatoid Arthritis
    • Jul 01, 2002: Genmab Announces The Human Antibody Therapeutic Drug HuMax-IL15 Effectively Treats Psoriasis
    • Oct 03, 2001: Genmab Initiates Phase I/II Clinical Trial With HuMax-IL15 For The Treatment Of Patients With Rheumatoid Arthritis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Amgen Inc., H1 2016
  • Pipeline by Calypso Biotech SA, H1 2016
  • Pipeline by Digna Biotech, S.L., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top